This is a Vertex news story, published by Investor's Business Daily, that relates primarily to Vertex Pharmaceuticals news.
For more Vertex news, you can click here:
more Vertex newsFor more stocks trading & speculation news, you can click here:
more stocks trading & speculation newsFor more news from Investor's Business Daily, you can click here:
more news from Investor's Business DailyOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best business news, entertainment news, world news, and much more. If you like stocks trading & speculation news, you might also like this article about
Vertex Pharmaceuticals. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest stock news, VRTX news, stocks trading & speculation news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Vertex stockInvestor's Business Daily
•
79% Informative
Vertex Pharmaceuticals beat Wall Street's third-quarter expectations late Monday .
Earnings climbed more than 7% and beat forecasts for $ 4.08 a share.
Sales rose 12% to $2.77 billion .
The lion's share of the sales came from Trikafta , Vertex 's latest-generation cystic fibrosis treatment.
VR Score
85
Informative language
94
Neutral language
15
Article tone
formal
Language
English
Language complexity
45
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
5
Source diversity
3
Affiliate links
no affiliate links